9月17日，Abivax S.A.盘中上涨5.06%，报107.4美元/股，成交额4550.79万美元。此前公司股价因财报营收预计下降逾四成的预期一度下挫超5%，本次反弹或受机构看多观点及核心管线积极进展提振。
消息面上，摩根士丹利此前将公司目标价由132美元上调至180美元，维持"增持"评级，指出obefazimod在溃疡性结肠炎领域展现出"广泛应用"潜力，专家对其疗效"几乎一致看好"。公司已明确计划于年底前向监管机构提交obefazimod首项新药申请，同时已完成约9.2亿美元ADS发行，净募资约8.74亿美元，可支持运营至2029年第四季度，现金流安全边际充裕。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.